Rubicon Research’s Rs 1,377 crore IPO concluded with strong investor demand, oversubscribing 109.35 times. The share allotment is scheduled for October 14, with the company set to list on the BSE and NSE on October 16. The pharmaceutical firm’s robust financial performance and differentiated product portfolio are driving positive market sentiment.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets